Compared with placebo, semaglutide lowered risks for adverse kidney outcomes and mortality across the chronic kidney disease spectrum, according to study data published in Clinical Journal of the ...

Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

Kidney or renal biopsy or puncture procedure concept photo. Getty Images New findings could help guide clinicians as to when to consider ordering kidney biopsies in patients with diabetes.

Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and ...

Among patients who underwent dialysis, those with diabetes as either the primary renal disease (PRD) or a comorbidity had a higher risk for lower limb amputation than those without. These patients ...

Learn how GLP-1s are changing type 2 diabetes care, when insulin therapy is still necessary, and the benefits of combining ...